M Frattini

Summary

Affiliation: Center for Experimental Pathology
Country: Switzerland

Publications

  1. ncbi PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    M Frattini
    Institute of Pathology, Via in Selva 24, CH 6600 Locarno, Switzerland
    Br J Cancer 97:1139-45. 2007
  2. ncbi Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
    F Molinari
    Institute of Pathology, Locarno, Switzerland
    Br J Cancer 100:1087-94. 2009
  3. ncbi Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features
    V Martin
    Institute of Pathology, Locarno, Switzerland
    Histol Histopathol 27:785-92. 2012
  4. ncbi An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
    V Martin
    Institute of Pathology, Locarno, Switzerland
    J Clin Pathol 62:314-24. 2009
  5. ncbi Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
    M Frattini
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Lett 263:170-81. 2008

Collaborators

Detail Information

Publications5

  1. ncbi PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    M Frattini
    Institute of Pathology, Via in Selva 24, CH 6600 Locarno, Switzerland
    Br J Cancer 97:1139-45. 2007
    ..In addition to K-Ras mutations, we demonstrate for the first time that the loss of PTEN protein expression is associated with nonresponsiveness to cetuximab...
  2. ncbi Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
    F Molinari
    Institute of Pathology, Locarno, Switzerland
    Br J Cancer 100:1087-94. 2009
    ....
  3. ncbi Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features
    V Martin
    Institute of Pathology, Locarno, Switzerland
    Histol Histopathol 27:785-92. 2012
    ..As a considerable fraction of TN-BCBLs shows EGFR deregulation, EGFR-targeted therapies have been proposed as an option. The characterization of EGFR and EGFR-downstream members may therefore provide important predictive information...
  4. ncbi An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
    V Martin
    Institute of Pathology, Locarno, Switzerland
    J Clin Pathol 62:314-24. 2009
    ..Further advances in improving the quality of care of patients with cancers characterised by EGFR gene deregulation will depend on answering some of the questions underlined throughout this overview...
  5. ncbi Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
    M Frattini
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Lett 263:170-81. 2008
    ..Therefore, combined quantitative and qualitative analyses of plasma DNA confirm the presence of colorectal cancer, define disease-free status and indicate the presence of relapse...